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Abstract
Malignant gliomas, especially glioblastomas, are associated with a dismal prognosis.
Despite advances in diagnosis and treatment, glioblastoma patients still have a median
survival expectancy of only 14 months.This poor prognosis can be at least partly explained
by the fact that glioma cells diffusely inﬁltrate the brain parenchyma and exhibit decreased
levelsofapoptosis,andthusresistancetocytotoxicdrugs.Galectinsareafamilyofmamma-
lian beta-galactoside-binding proteins characterized by a shared characteristic amino acid
sequence. They are expressed differentially in normal vs. neoplastic tissues and are known
to play important roles in several biological processes such as cell proliferation, death and
migration. This review focuses on the role played by galectins, especially galectin-1 and
galectin-3,ingliomabiology.Theinvolvementofthesegalectinsindifferentstepsofglioma
malignant progression such as migration, angiogenesis or chemoresistance makes them
potentially good targets for the development of new drugs to combat these malignant
tumors.
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GLIOMAS: AN OVERVIEW
Gliomas account for more than 50% of all primary brain tumors
and are by far the most common primary brain tumor in adults (71,
73, 77). Gliomas include tumors that are composed predominantly
of astrocytes (astrocytomas), oligodendrocytes (oligodendroglio-
mas),ependymalcells(ependymomas)oramixtureofvariousglial
cells (eg, oligoastrocytomas) (77).The World Health Organization
grading system classiﬁes gliomas into grade I to IV based on the
degree of malignancy, as determined by histopathological criteria.
Grade I gliomas are generally well circumscribed and behave in a
benignfashion,whereasgradeIIthroughIVgliomasaremalignant
and diffusely inﬁltrate the brain (77). Among gliomas, astrocyto-
mas are the most common and are comprised of pilocytic astrocy-
tomas(gradeI),diffuseastrocytomas(gradeII),anaplasticastrocy-
tomas (grade III) and glioblastoma (grade IV) (77). Glioblastomas
are characterized by a very dismal prognosis (74, 113). Glioblas-
tomapatientshaveamediansurvivalexpectancyofonly14months
when on the current standard treatment of surgical resection to the
extent feasible, followed by adjuvant radiotherapy plus temozolo-
mide chemotherapy, given concomitantly with and after radio-
therapy (73, 74, 87).
Malignant gliomas are associated with such dismal prognoses
because glioma cells can actively migrate through the narrow
extracellular spaces in the brain, often traveling relatively long
distances, making them elusive targets for effective surgical man-
agement (16, 33, 47, 71).Additionally, after surgical resection and
adjuvant treatment of malignant gliomas, the residual cancer cells
peripheraltotheexcisedlesiongiverisetoarecurrenttumorthatin
more than 90% of cases develops immediately adjacent to the
resection margin (33, 46, 71).
Clinicalandexperimentaldatahavealsodemonstratedthatinva-
sive malignant glioma cells show a decrease in proliferation rate
and a relative resistance to apoptosis as compared with the highly
dense cellular center of the tumor, and this may contribute to their
resistance to conventional pro-apoptotic chemotherapy and radio-
therapy (33, 46, 71, 72). One way to potentially overcome resis-
tance to apoptosis is to decrease the migration of malignant glioma
cells in the brain, which should then theoretically restore a level of
sensitivity to cytotoxic drugs (54, 64, 72, 82).
GALECTINS: AN OVERVIEW
Galectins are a structurally related family of animal lectins deﬁned
by two properties: (i) an afﬁnity for b-galactoside sugars; and (ii) a
sequence homology (2, 3, 19, 75).This consensus sequence corre-
sponds to the carbohydrate-recognition domain (CRD), which is a
beta sandwich of about 135 amino acids long and is responsible for
b-galactoside binding (2, 3, 19, 75).To date 15 galectins have been
characterized; they are numbered according to the chronology of
Brain Pathology ISSN 1015-6305
17 Brain Pathology 20 (2010) 17–27
© 2009 The Authors; Journal Compilation © 2009 International Society of Neuropathologytheir discovery (galectin-1 to galectin-15) (2, 3, 19, 75).The galec-
tins known so far have either one or two CRDs within a single
polypeptidechain,andeachCRDisnotassociatedwithothertypes
of well-deﬁned protein domains. The mono-CRD galectins can
be biologically active as monomers (galectin-5, -7, -10) or as
homodimers (galectin-1, -2, -11, -13, -14, -15); the bi-CRD galec-
tins (galectin-4, -6, -8, -9, 12) are active as monomers and might
also associate into oligomers (69, 70). Galectin-3, a mono-CRD
galectin, is unique in that it contains a short proline, glycine and
tyrosine rich N-terminal domain fused onto the CRD that therefore
allows the formation of oligomers (69, 70). Galectins show a
high level of evolutionary conservation, whereby members of this
family are present in organisms from nematodes to mammals
(49).
Galectins can segregate into multiple cell compartments.
Although these proteins lack the signal sequence that would be
required for secretion through the classical secretory pathway,
somegalectinsshowextracellularlocalization,suggestingthatthey
are secreted through a non-classical pathway (51, 92, 116). Galec-
tins are present both inside and outside cells. They function extra-
cellularly by interacting with cell surface and extracellular matrix
(ECM) glycoproteins and intracellularly by interacting, in a
carbohydrate-independent manner, with cytoplasmic and nuclear
proteins (24, 42, 75, 101). They play a role in a wide range of
processes, including cell adhesion, regulation of cell growth, apop-
tosis, embryonic development and immune processes-like inﬂam-
mation (13, 24, 43, 44, 75, 88, 97, 101, 114).
A large amount of experimental evidence has been reported to
support the important roles of galectins in cancer biology (19, 23,
24, 75, 115), including tumor angiogenesis (56, 65, 123–125),
tumorimmuneescape(96,106,112)andcancercellmigration(35,
45,53,86,134).Inthecurrentreview,wefocusourattentiononthe
biological roles exerted by galectins in gliomas.
GALECTINS THAT COULD BE
IMPLICATED IN GLIOMA BIOLOGY
The group ofA. Raz was among the ﬁrst to demonstrate a relation-
ship between galectin expression and the malignant potential of
tumors in the central nervous system (9). Indeed, they have shown
that the expression level of galectin-3 was signiﬁcantly associated
with astrocytic tumor grade (9). In contrast, Gordower et al found
that the level of galectin-3 expression signiﬁcantly decreases in the
majority of astrocytic tumors from low to high grade. However,
they also observed that some highly malignant tumor cell clones
expressed high amounts of galectin-3 (36). Numerous other
studies have also conﬁrmed that astrocytic tumors express high
levels of galectin-3 (61, 91, 119, 121, 122). With regard to the
other types of glioma, Bressalier et al have reported that galectin-3
was not expressed in oligodendrogliomas or ependymomas (9). In
another study, galectin-3 expression was shown to be signiﬁcantly
higher in glioblastomas and pilocytic astrocytomas than in oligo-
dendrogliomas, anaplastic oligodendrogliomas and diffuse
astrocytomas (91). Finally, it was reported that galectin-3 was
expressed in oligodendrocytes, endothelial cells and macrophages/
microglial cells in areas of solid tumor growth (22). In this study,
Deininger et al showed that signiﬁcantly fewer galectin-3 positive
oligodendroglioma cells and macrophages/microglial cells were
detected in grade II oligodendrogliomas than in grade III anaplas-
tic oligodendrogliomas. On the contrary, signiﬁcantly more
galectin-3 positive endothelial cells were detected in grade II than
in grade III oligdendrogliomas (22). Moreover, in an attempt to
reconcile the conﬂicting results published on galectin-3 expression
in human gliomas, Strik et al have used immunohistochemistry
to identify the cellular origin and extent of galectin-3 positivity
in glioma samples (119). They have shown in this study that
galectin-3 was expressed in neoplastic astrocytes, macrophages/
microglial cells, endothelial cells and some B- andT-lymphocytes.
They also pointed out that galectin-3 positivity was considerably
inﬂuenced by tumor-inﬁltrating macrophages (119). The expres-
sion level of galectin-3 seems then to be highly dependent on
non-tumor cells such as endothelial cells or macrophages/
microglial cells.This feature can thus partly explain the conﬂicting
results that have been published on galectin-3 expression in human
gliomas (22, 119).
The regulation of galectin-3 expression by Runx-2 has been
recently suggested to contribute to the malignant progression
of glial tumor (128). Runx2 is a member of the Runx family of
transcription factors expressed in a variety of human glioma cells,
whoseexpressionpatterninthesecellsstronglycorrelateswiththat
of galectin-3, but not with that of other galectins (128). Knock-
down of Runx2 was shown to be accompanied by a reduction in
both galectin-3 mRNA and protein levels by at least 50%, depen-
dent on the glial tumor cell line tested (128).
The role of galectin-1 in glioma biology was ﬁrst suggested by
Yamaoka et al (131) and Gunnersen et al (39). They have ana-
lyzed the mRNA expression of galectin-1 by northern blot in
glioma specimens and glioma cell lines. Increased expression of
galectin-1 mRNA was shown to correlate with increased malig-
nancy in human astrocytic tumors ranging from low-grade
astrocytomas to malignant gliomas (131). However, no statistical
analysis was made (131). Two studies from our own group using
clinical samples have shown that galectin-1 is expressed in all
glioma types and that the level of galectin-1 expression correlates
directly with the grade of the astrocytic tumor (10, 105). Speciﬁ-
cally, we quantitatively determined (by computer-assisted micros-
copy) the immunohistochemical expression of galectin-1 in 220
gliomas, including 151 astrocytic, 38 oligodendroglial and 31
ependymal tumors (105). Our data revealed the expression of
galectin-1 in all human glioma types with no striking variation in
levels among astrocytic, oligodendroglial and ependymal tumors;
the level of galectin-1 expression within astrocytic tumors,
however, signiﬁcantly correlated with tumor grade (105). Further-
more, expression levels of galectin-1 in high-grade astrocytic
tumors from patients with short-term survival periods were sig-
niﬁcantly higher than those in tumors from patients with long-
term survivals (105).
Very little is known about the expression of other galectins in
brain tumors. A reverse transcription polymerase chain reaction
analysis has shown that galectin-1, -2, -4, -7, -8 and -9 are
expressed in normal human brain (111). In another study, Lahm
et al have examined the expression of a panel of galectins, includ-
ing galectin-1, -2, -3, -4, -7, -8 and -9, in eight glioma cell lines
(62). Galectin-1, -3 and -8 were the most abundantly expressed in
all the cell lines. Galectin-2 was expressed in only one cell line,
galectin-4 and -9 were expressed weakly in three cell lines, and no
evidence for the presence of galectin-7 mRNA was found among
any of the cell lines (62).
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GALECTINS AND INTEGRINS
Galectins are components of the ECM. The ECM comprises all
secretedsolubleandinsolublemoleculesfoundwithintheextracel-
lular ﬂuid of the extracellular space. The ECM is not only a static
scaffoldingfortissueorganizationbutitisinvolvedaswellinmany
regulatory functions like modulation of migration, guidance of
axonal growth, synapse formation and cell proliferation. Several
reviews have already addressed an in-depth analysis of glioma
ECM. We thus cite these reviews without commenting on them,
keeping in mind that the current review aims to analyze the roles of
galectins in glioma biology. These reviews include the pioneering
work of J.T. Rutka (107–109) among others (5, 15, 34, 47, 63, 71,
87, 103, 129).
As emphasized by Uhm et al (127), integrins are cell-surface
receptors that mediate the physical and functional interactions
between a cell and its surrounding ECM. Integrins consist of two
non-covalently associated transmembrane glycoprotein subunits
alpha and beta, both of which contribute to the binding of ECM
components. To date 18 different a-subunits and 8 different
b-subunits have been identiﬁed, which associate to form 25 recog-
nized ab heterodimers (48). The speciﬁc alpha or beta chains that
constitute the integrin receptor determine the repertoire of ECM
proteins to which a speciﬁc integrin may bind. Moreover, many
integrin ligands exhibit a speciﬁc three-amino acid sequence
labeled arginine–glycine–aspartate (RGD), a sequence that is
present in most ECM components (48). Although classically the
role ascribed to integrins has been that of anchoring cells to the
ECM, the functions of integrins greatly exceed that of mere cell
adhesion (127). Within this multifaceted role, integrins have been
shown to be molecular determinants of glioma invasion (5, 6, 18,
90, 110).
Galectins and integrins closely interact when modulating cell
adhesion and/or cell migration. For example, Moiseeva et al have
shown that galectin-1 interacts with the integrin b1 subunit in vas-
cular smooth muscle cells (85) (Figure 1).Via its direct binding to
b1 integrins (without cross-linking), dimeric galectin-1 increases
Figure 1. Galectins, integrins and cell migration. The interaction of
galectins with integrins modulates cell migration as well as other pro-
cesses. Galectin-1 (Gal-1) interacts with the b1 integrin subunit inducing
the phosphorylation of FAK, which modulates cell migration (85). Binding
of Gal-1 to integrin is involved in cell adhesion (83). Moreover, Gal-1 was
shown to regulate the expression of the protein ADAM-15 that is
involved in integrin-mediated adhesion (12). Gal-1 also induces growth
inhibition via its interaction with a5b1 (26). This interaction results in the
inhibition of the Ras–MEK–ERK pathway and the consecutive transacti-
vation of Sp1, which induces p27 transcription (26). In addition, Gal-1 is
involved in the PKCe/vimentin controlled trafﬁcking of integrin b1, a
process that is important for cell migration (28). However, it is not known
with which molecule(s) Gal-1 is interacting, or in which intra- or extracel-
lular location this interaction is taking place in order to initiate this signal-
ing. Finally, Gal-1 is also involved in cell motility via the Gal-1-induced
expression of RhoA and the alteration of the polimerization of the actin
cytoskeleton (11) Once again, the receptor to which Gal-1 bind to initiate
this signaling is not known. Galectin-3 (Ga-3) regulates cell adhesion via
binding to a1b1 (94). Gal-3 also forms a complex with a3b1 and the
proteoglycan NG2 (31). This interaction regulates endothelial cell motility
and angiogenesis. Finally, Gal-3 has been shown to regulate the expres-
sion of integrin a6b1 and actin cytoskeleton organization (20). However,
it is not known with which molecule(s) Gal-3 is interacting to initiate this
signaling. Galectin-8 (Gal-8) interacts with several integrins including
a1b1, a3b1, a5b1 and a6b1. These interactions are involved in cell
adhesion and apoptosis (40). Abbreviations: ERK = extracellular signal-
regulated kinase; FAK = focal adhesion kinase; MEK = MAP kinase/
extracellular signal-regulated kinase kinase (MAPK/ERK Kinase);
PKCe=protein kinase C epsilon.
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dimerization with a subunits (85). In the case of vascular smooth
muscle cells, this interaction of galectin-1 with a1b1 integrin has
been reported to both transiently phosphorylate focal adhesion
kinase and modulate cell attachment, spreading and migration on
laminin, but not on cellular ﬁbronectin (38, 85).Thus galectin-1 is
likely to affect smooth muscle cell adhesion by interacting with b1
integrin on the cell surface and inducing outside-in signaling (85)
(Figure 1).
Galectin-1 also interacts with a5b1 integrin to restrict epithelial
tumor cell growth (26) (Figure 1). Indeed, Fischer et al have
observed that the anti-proliferative potential of galectin-1 in a
number of carcinoma cell lines requires functional interaction with
the a5b1 integrin (26) (Figure 1). Furthermore, we recently
showed that the depletion of galectin-1 in various human glioma
cell lines through both stable knockdown and transient targeted
small-interfering RNA (siRNA) treatment induces an intracellular
accumulation of integrin-b1 coincident with a diminution of
integrin-b1 at points of cellular adhesion at the cell membrane,
without altering the b1 gene expression level (28). Transient
galectin-1 depletion effectuates as well the perinuclear accumula-
tion of protein kinase C epsilon (PKCe) and the intermediate ﬁla-
ment vimentin, both of which have been shown to promote integrin
recycling in motile cells (28).These data argue for the involvement
of galectin-1 in the PKCe/vimentin controlled trafﬁcking of
integrin-b1 (28) (Figure 1).
Galectin-3 was also shown to bind to a1b1 integrin and it was
suggested that this interaction regulates cell adhesion of various
tumor cell lines by preventing a1b1 integrin interaction with the
ECM proteins (94) (Figure 1). Galectin-3 also forms a complex
with a3b1 integrins and NG2 on the surface of endothelial cells.
The subsequent transmembrane signaling via a3b1 has been
shown to be responsible for endothelial cell motility and angiogen-
esis (31) (Figures 1 and 2).
Finally, galectin-8 was also reported to interact with a subgroup
ofintegrinsthatincludea3b1,a6b1,andtoalesserextentwiththe
a4 and the b3 subunits in human carcinoma (1299) cells (40).
These interactions were shown to inhibit cell adhesion and to
induce apoptosis (40). More recently, galectin-8 was shown to bind
a1b1, a3b1 and a5b1 integrins in JurkatT cells (14) (Figure 1).
As the aforementioned indicates, integrins are known to play a
signiﬁcant role in the malignant progression of cancer cell through
theirinvolvementincelladhesion,motilityandintracellularsignal-
ing (1, 41, 52), with an emphasis on the role of the beta 1 integrin
subunit in gliomas (4, 6, 18, 95). As galectins bind integrins, with
galectin-1, galectin-3 and galectin-8 all known speciﬁcally to
Figure 2. Presumed role of galectins in angiogenesis and chemoresis-
tance. Necrotic foci in glioblastoma are typically surrounded by hypercel-
lular zones referred to as pseudopalisades (104). It has been shown that
pseudopalisades are hypoxic and express high amounts of the transcrip-
tion factor hypoxia-inducible factor 1 (HIF-1) (104). Galectin-3 (Gal-3)
expression is stimulated by hypoxia via HIF-1 (132) and stimulates angio-
genesis in vitro and in vivo (89). Gal-3 has also been shown to interact
with NG2 proteoglycan, a component of microvasculature pericytes,
which stimulates endothelial cell motility and morphogenesis (130). In
addition, Gal-3 is involved in chemoresistance, a process that is
increased in hypoxic conditions (30). Galectin-1 (Gal-1) expression is also
stimulated in hypoxic conditions (67), however, it is not known if this is
HIF-1-dependent. Recent evidence indicates that Gal-1 plays an impor-
tant role in angiogenesis and in chemo- and radioresistance (64, 120).
These effects of Gal-1 can be explained at least partly by the fact that
Gal-1 modulates the unfolded protein response (UPR), a process that is
involved in resistance and angiogenesis (64, 65). Moreover, Gal-1 was
shown to control the expression level of the UPR-regulated protein
ORP150, which is responsible for vascular endothelial growth factor
(VEGF) maturation and secretion (65).
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mediators such as galectins and the pathways through which they
drive the cell invasion so descriptive of glioblastoma multiforme
(GBM) is anticipated to reveal potential therapeutic targets that
promote glioma malignancy (28). Indeed, targeting both integrins
and galectins represents a feasible proposition in the future treat-
mentofgliomas;alreadythereisevidenceamountingthatatteststo
this. For example, the small a5b1 integrin antagonist, SJ749,
reduces proliferation and clonogenicity of human astrocytoma
cells (78). Moreover, impairing galectin-1 expression in vivo
in experimental gliomas through the delivery of anti-galectin-
1 siRNA augments the therapeutic beneﬁts contributed by
temozolomide (65).
GALECTINS AND GLIOMA CELL
MIGRATION
Cell migration involves at least three independent but highly coor-
dinated biological processes: (i) cell adhesion to numerous compo-
nents of the ECM; (ii) cell motility, which involves the reorganiza-
tion of the actin cytoskeleton mainly through modiﬁcation of
the components of the adhesion complex; and (iii) invasion that
involves the degradation of matrix proteins by tumor-secreted pro-
teolytic enzymes, mainly serine proteases, cathepsins and metallo-
proteinases (MMPs) (21, 71, 103).
Galectins are involved in each of these steps (118). For example,
galectin-1, galectin-3 and galectin-8 have been shown to inﬂuence
glioma cell migration (10) (Figure 1). The expression of these
galectins was shown to be higher in the invasive parts of
xenografted glioblastomas than in the less invasive parts, suggest-
ing their involvement in tumor astrocyte invasion of the brain
parenchyma (10). In addition, galectin-1, galectin-3 and to a lesser
extent galectin-8, markedly stimulate the migration of glioma cell
lines (U373 and U87) in vitro (10) (Table 1). Moreover, galectin-3
biological functions were reported to be modulated by MMPs (93,
94), which play crucial roles in glioma cell motility and invasion
(103). McClung et al (81) have shown by cDNA array analysis
that secreted protein acidic and rich in cysteine, which is highly
expressed in human gliomas and promotes glioma invasion,
upregulates membrane type 1-matrix MMP and matrix MMP-2
transcripts, coincident with both increases in secreted galectin-3
and the proteolytically processed form of galectin-3. This concur-
rent stimulation of MMPs and galectin-3 supports a role for
galectin-3 in glioma motility. However, in disagreement with the
aforementioned, cultured galectin-3 deﬁcient U373 glioblastoma
cells, obtained by a stable transfection with a speciﬁc expression
antisenseplasmid,havebeenshowntobothhaveincreasedmotility
potential on laminin and display modiﬁcations in cytoskeleton
reorganization (20) (Table 1, Figure 1). c-DNA microarrays and
quantitative immunoﬂuorescence analysis showed that these
Table 1. Biological functions of galectins in gliomas. Abbreviation: CRD = carbohydrate-recognition domain.
Galectins Structures Cell types expressing and
inﬂuenced by galectins in
glioma context
Biological functions
in gliomas
Presumed mechanism of
action in glioma context
Intracellular (IC)
or extracellular
(EC) role
References
Galectin-1 Mono-CRD Astrocytes
Oligodendrocyte
Ependymocyte
Endothelial cells
Perivascular cells
Cell migration ￿ Modulation of
cytoskeleton organization
EC (11)
￿ Modulation of RhoA
expression
EC (11)
￿ Modulation of ADAM-15
expression
Unspeciﬁed (12)
￿ Modulation of integrin b1
recycling
Unspeciﬁed (28)
Angiogenesis ￿ Regulation of VEGF
secretion via the
regulation of ORP150
expression
Unspeciﬁed (17, 65, 123)
Chemo-/
Radioresistance
￿ Regulation of the
endoplasmic reticulum
stress response
Unspeciﬁed (64, 120)
￿ Modulation of p53
transcriptional activity
Unspeciﬁed (64)
Galectin-3 Mono-CRD with an
N-terminal domain
Astrocytes
Oligodendrocytes
Endothelial cells
Perivascular cells
Macrophages/
microglial cells
Cell migration ￿ Modulation of
cytoskeleton organization
Unspeciﬁed (20)
￿ Modulation of integrins-a6
and -b1 expression
Unspeciﬁed (20)
Angiogenesis ￿ Interaction with NG2
proteoglycan on pericytes
EC (36, 89)
Galectin-8 Bi-CRD Astrocytes
Perivascular cells
Cell migration Unknown EC (10)
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integrins-a6 and -b1 (20) (Figure 1). Although this study shows
results that appear to contradict those of Camby et al, this could be
partly explained by differences in the experimental procedures.
Indeed,Debrayet alhaveshownanincreasedmotilityofgalectin-3
deﬁcientcellscultivatedonlaminin(20)whereasCambyet alhave
observed an increase of motility when glioma cells were cultivated
on plastic pre-coated with galectin-3 (10).
Our group has focused on the role of galectin-1 in glioma cell
migration. We xenografted three human glioblastoma cell lines
(H4, U87 and U373) into the brains of nude mice in order to
characterize the in vivo galectin-1 expression pattern in relation
to the tumor invasion of the normal brain parenchyma. The
immunohistochemical analysis of galectin-1 expression in human
U87 and U373 glioblastoma xenografts revealed a higher level of
galectin-1 expression in invasive areas as compared to the non-
invasive areas of the xenografts (11, 105). Moreover, nude mice
intracranially grafted with U87 or U373 cells that were constitu-
tively expressing low levels of galectin-1 (by stable transfection
with an expression vector containing the antisense galectin-1
mRNA) had longer survival periods than those grafted with U87
or U373 cells unchanged in expression levels of galectin-1 (11).
Complementary studies have shown that the in vitro addition of
puriﬁed galectin-1 to U87 human GBM cells enhanced tumor cell
motility in a lactose-inhibited manner (12) (Table 1). This effect
appeared to be related to an increase in polymerized ﬁlamentous
actin and the expression of the small guanosine triphosphatase
RhoA (11) (Figure 1).
Finally, using cDNA microarray analysis and conﬁrmation at
protein levels, we observed that the U87 GBM cells that were
galectin-1 deﬁcient by means of an antisense galectin-1-stable
transfection displayed increased protein levels for p21waf/cip1,
cullin-2,p53,ADAM-15andMAP-2(12).Majordifferencesinthe
expression patterns ofADAM-15 and in the actin stress ﬁber orga-
nizationwerealsoobserved(12).TheADAMfamilyofmembrane-
anchorage glycoproteins encompasses a catalytically active MMP
domain and a disintegrin domain (98) and may thus be involved
both in the proteolytic cleavage of cell-surface proteins and in
integrin-mediated cell adhesion (including alpha9beta1 integrin/
ADAM-15 interactions) via the RGD-dependent and -independent
binding (25) (Figure 1).
All these data indicate that galectin-1 enhances the migratory
capabilities of tumor astrocytes and, therefore, their biological
aggressiveness. These features have been recently conﬁrmed by
Strik et al (120), and by Jung et al (57).
GLIOMA, HYPOXIA, ANGIOGENESIS
AND GALECTINS
Progression-associated genetic alterations are common to different
glioma types, and target growth-promoting and cell-cycle control
pathways resulting in focal hypoxia, necrosis and angiogenesis
(76). GBM is distinguished pathologically from lower grade
tumors by necrosis and microvascular hyperplasia (76). Necrotic
foci are typically surrounded by “pseudopalisading” cells—a
conﬁguration that is relatively unique to malignant gliomas and
has long been recognized as an ominous prognostic feature
(Figure 2) (76, 104). Recent investigations have demonstrated
that pseudopalisades are severely hypoxic, overexpress hypoxia-
inducible factor 1 (HIF-1), and secrete proangiogenic factors such
as vascular endothelial growth factor (VEGF) and IL-8 (104)
(Figure 2). Pseudopalisades could represent a wave of tumor cells
actively migrating away from central hypoxia that arises after a
vascular insult (104). HIF-1 is one of the master regulators that
orchestrate the cellular responses to hypoxia; it is a heterodimeric
transcription factor composed of alpha and beta subunits (58).
The alpha subunit is stable in hypoxic conditions but is rapidly
degraded in normoxia; upon stabilization or activation, HIF-1
translocates to the nucleus and induces transcription of its down-
stream target genes (58). Most relevant to gliomagenesis, HIF-1 is
a potent activator of angiogenesis and invasion through its upregu-
lation of target genes critical for these functions; activation of the
HIF-1 pathway is a common feature of gliomas and may explain
the intense vascular hyperplasia often seen in GBM (27, 32, 58).
The expression of galectin-3, which is the most extensively
studied member of the galectin family in the ﬁeld of angiogenesis
(89, 125) and with speciﬁc regard to gliomas (36, 130) (Table 1),
has been shown to be stimulated upon HIF-1 activation (37, 50,
117, 132) (Figure 2). It has been shown that galectin-3 promotes
chemotaxis and morphogenesis of endothelial cells and stimulates
capillary tube formation in human umbilical vein endothelial cells
in vitro (89). Moreover, galectin-3 was also reported to stimulate
angiogenesis in vivo in breast cancer cell lines injected subcutane-
ouslyintothedorsolateralregionofnudemice(89).Galectin-3was
also shown to interact with NG2 proteoglycan, a component of
microvascular pericytes, which stimulates endothelial cell motility
and morphogenesis. This function of NG2 on cell motility and
morphogenesis depends on the formation of a complex with
galectin-3 and a3b1 integrin to stimulate integrin-mediated trans-
membrane signaling (31, 130) (Figure 2).
Galectin-1 is also a hypoxia-regulated protein (7, 67, 68) that
has been shown recently to display major roles in angiogenesis
(17, 123), in both gliomas (65) (Table 1) and melanomas (80)
(Figure 2). Galectin-1 involvement in tumor angiogenesis was ﬁrst
suggestedafterthediscoverythatbothvascularsmoothmuscleand
endothelial cells express the protein (84). Clausse et al had also
previously shown that galectin-1 was upregulated in capillaries
associated with carcinoma cells and found that galectin-1 could
mediate interactions between tumors and endothelial cells in vitro,
suggesting a potential role for galectin-1 in modulating angiogen-
esis (17). Finally, Thijssen et al have shown that both treatment
with galectin-1 speciﬁc antisense oligodeoxynucleotides or with
polyclonal anti-galectin-1 antibodies resulted in inhibition of
endothelial cell proliferation and migration, demonstrating an
essential role for galectin-1 during angiogenesis (123).The role of
galectin-1 in tumor angiogenesis is further highlighted in galectin-
1-null mice, in which tumor growth is markedly impaired because
of insufﬁcient tumor angiogenesis (123).
We ourselves have also put forward evidence for the role of
galectin-1intheprocessofangiogenesisusinghumangliomacells.
To determine how galectin-1 exerts its pro-angiogenic effects, we
investigated galectin-1 signaling in the human Hs683 glioma cell
line. We observed that galectin-1 signals through the endoplasmic
reticulum transmembrane kinase/ribonuclease inositol-requiring
1alpha (IRE1alpha) that regulates the expression of oxygen-
regulated protein 150 (ORP150), which in turn controls VEGF
maturation (Figure 2). Galectin-1 also modulates the expression of
six other hypoxia-related genes (ie, CTGF, ATF3, PPP1R15A,
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(65). Moreover, we have recently reported that downregulating
galectin-1 expression in Hs683 human glioma cells through tar-
geted siRNA provokes a marked decrease in the expression of the
brain expressed X-linked gene (BEX2), a feature which confers
increased survival in Hs683 orthotopic xenograft-bearing mice.
This decrease in BEX2 expression impairs vasculogenic mimicry
channel formation in vitro and angiogenesis in vivo, and modulates
glioma cell adhesion, motility and invasive features (66).
GLIOMA HYPOXIA,
CHEMO-/RADIORESISTANCE AND
GALECTINS
Resistance of human tumors to anticancer drugs is most often
ascribed to gene mutations, gene ampliﬁcation or epigenetic
changes that inﬂuence the uptake, metabolism or export of drugs
from single cells (126). Another important yet little-appreciated
cause of anticancer drug resistance is the limited ability of drugs to
penetrate tumor tissue and to reach all of the tumor cells in a
potentially lethal concentration (126).Although now recognized as
a major contributor to cancer malignant progression and to treat-
ment failure, the precise role of hypoxia signaling in cancer and in
prognosis still needs to be further deﬁned (8). As emphasized
earlier, intra-tumoral hypoxia causes genetic changes in malignant
gliomas that produce a microenvironment that selects for cells of a
more aggressive phenotype (55, 104). Hypoxia can initiate cell
demisebyapoptosis/necrosisbutalsopreventcelldeathbyprovok-
ing adaptive responses that, in turn, facilitate cell proliferation or
angiogenesis, thus contributing to tumor malignant progression
(133).ZhouJet al(133)emphasizethatconsideringthatactivation
of HIF-1 provokes pro-survival as well as pro-death decisions
under hypoxia, it will be crucial to understand decision making
processes in regulating cell death, adaptation and chemoresistance.
Hypoxia is also known to modulate the unfolded protein response,
acoordinatedprogramthatpromotescellsurvivalunderconditions
of endoplasmic reticulum (ER) stress (60), and which is known to
contribute to tumor malignant progression and drug resistance of
solid tumors (59).
As mentioned earlier, hypoxia is known to activate galectin-1
expression (7, 67, 68), and galectin-1 was found to be negatively
regulated by transfection withTP53 in glioma cells (99).
We recently reported that temozolomide, the standard treatment
for glioma patients (74), increases galectin-1 expression in Hs683
gliomacellsbothinvitroandinvivo.Inaddition,galectin-1expres-
sion was shown to be upregulated by ionizing irradiation of glioma
cell lines in vitro (120). Reducing galectin-1 expression in these
cells by siRNA increases the antitumor effects of various chemo-
therapeutic agents, in particular temozolomide both in vitro and in
vivo in a orthotopic xenograft mouse model (64) (Table 1,
Figure 2). We also observed that decreasing galectin-1 expression
by means of an anti-galectin-1 siRNA in the mouse B16F10 meta-
static melanoma model, which is a syngenic model whereby
B16F10 melanoma cells are injected in the tail vein, also increases
the therapeutic beneﬁts contributed by temozolomide in vivo (80).
This decrease of galectin-1 expression in the B16F10 mouse mela-
noma cells does not modify their sensitivity to apoptosis nor
autophagy.However,itdoesinduceheatshockprotein70-mediated
lysosomal membrane permeabilization (LMP), a process associ-
ated with cathepsin B release into the cytosol, which in turn is
believed to sensitize the cells to the proautophagic effects of temo-
zolomide when grafted in vivo (80). In Hs683 glioma cells a
decrease in galectin-1 expression does not induce apoptotic or
autophagic features and does not induce LMP, but is found to
modulate p53 transcriptional activity and decrease p53-targeted
gene expression including DDIT3/GADD153/CHOP, DUSP5,
ATF3 and GADD45A (64). In addition the decrease in galectin-1
expressionimpairstheERstressresponse,whichisbelievedtoplay
aroleindrugresistance(79),andalsoimpairstheexpressionlevels
of seven other genes implicated in chemoresistance: ORP150;
HERP; GRP78/Bip; TRA1; BNIP3; GADD45B; and CYR61, some
ofwhicharealsoknowntobemodiﬁedbyhypoxia(64).
Similar to galectin-1, galectin-3 is also a hypoxia-regulated
protein (37, 50, 117, 132) that is implicated in cancer drug resis-
tance (29, 30) (Figure 2). Galectin-3 confers chemoresistance to a
wide variety of cancer cell types (30). Recent studies have revealed
that galectin-3 demonstrates anti-apoptotic effects, which contrib-
ute to cell survival in several types of cancer cells (88). In particu-
lar, intracellular galectin-3, which contains the NWGR anti-death
motifoftheBcl-2family,inhibitscellapoptosisinducedbychemo-
therapeutic agents such as cisplatin and etoposide in some types of
cancercells(88).Ithasalsobeenreportedthatthenuclearexportof
phosphorylated galectin-3 regulates its anti-apoptotic activity in
response to chemotherapeutic drugs. Indeed anticancer drugs can
induce DNA damage, which causes phosphorylated galectin-3 to
translocate from the nucleus to the cytoplasm and regulates phos-
phorylation of Bad, Akt and extracellular signal-regulated kinase
resulting in stabilization of mitochondrial membrane integrity.The
stabilization of the mitochondrial membrane prevents cytochrome
c release and subsequent caspase activation, resulting in the sup-
pressionofapoptosisandanticancerdrugresistance(30).Finally,it
has been suggested that targeting galectin-3 could improve the
efﬁcacyofanticancerdrugchemotherapyinseveraltypesofcancer
(30). However, the involvement of galectin-3 in the chemo- and/or
radioresistance of gliomas has not yet been demonstrated, at least
to the best of our knowledge.
CONCLUSIONS
Galectins are known to play an important role in cancer malignant
progression (75). Speciﬁcally, galectin-1, galectin-3 and to a lesser
extent galectin-8 have been reported to be implicated in glioma
malignant progression (Table 1). Galectin-1 especially is involved
in many different steps of tumor biology, such as migration, angio-
genesis and resistance to chemotherapy and radiotherapy. More-
over, galectin-1 is also involved in tumor immune escape, however
not in gliomas (96, 102). Although there is much to learn about
the actual mechanisms by which galectins inﬂuence glioma cell
biology and much to explain regarding some conﬂicting results
obtained in different studies, the data reviewed here may be
amenable to therapeutic manipulation. We have already shown
that decreasing galectin-1 expression in human GBM orthotopic
xenografts in mouse brains by siRNA administration enhances the
therapeutic beneﬁts of temozolomide (65). Thus, galectins and
especially galectin-1 could be important targets for the develop-
ment of new anticancer drugs not only for gliomas but for other
types of cancer as well (53, 100).
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